micrometastases

Related by string. * * *

Related by context. All words. (Click for frequent words.) 72 lymph node metastases 72 adenoma 71 invasive carcinoma 71 liver metastases 71 distant metastases 70 metastases 70 lobular carcinoma 70 micrometastasis 70 advanced adenomas 70 metastatic tumors 70 PCa 70 prostate cancer CaP 70 bone metastasis 69 adenomatous polyps 69 GISTs 69 pCR 69 colorectal carcinoma 69 metastatic lesions 69 axillary lymph nodes 69 occult metastases 69 neoadjuvant therapy 69 adenocarcinomas 68 pelvic lymphadenectomy 68 axillary nodes 68 breast carcinoma 68 mucinous 68 distant metastasis 68 sentinel nodes 68 sentinel lymph nodes 68 advanced adenoma 68 p# mutations 67 sentinel node 67 renal tumors 67 ALND 67 lymph node involvement 67 MGUS 67 malignancy 67 locoregional recurrence 67 metachronous 67 radical nephrectomy 67 preoperative chemotherapy 67 EUS FNA 67 breast carcinomas 67 renal cell carcinomas 67 ductal carcinomas 67 sentinel lymph node biopsy 67 neoplasm 67 nodal metastasis 66 tumor recurrence 66 lymphovascular invasion 66 intestinal metaplasia 66 ADPKD 66 lung nodules 66 tumors 66 supratentorial 66 seminomas 66 urothelial carcinoma 66 atypical hyperplasia 66 cystectomy 66 NMIBC 66 epithelial tumors 66 neoadjuvant chemotherapy 66 pulmonary metastases 66 metastasis 66 EGFR mutation 66 p# mutation 66 pancreatic adenocarcinoma 66 axillary node 66 nodal metastases 66 prostate carcinoma 66 hamartomas 66 neoplastic cells 66 cisplatin resistant 65 HGPIN 65 sentinel lymph node 65 GIST tumors 65 thyroglobulin 65 proximal colon 65 hyperplastic 65 adjuvant radiotherapy 65 node metastases 65 advanced neoplasia 65 differentiated thyroid 65 resectable 65 colorectal tumors 65 adenomatous 65 lymph node metastasis 65 axillary lymph node dissection 65 esophagogastric junction 65 lymphadenectomy 65 tumoral 65 contralateral breast 65 axillary node dissection 65 EGFR mutations 65 histologically 65 liver metastasis 65 GBM tumors 65 thyroid nodules 65 axillary dissection 65 atypia 65 lymph node dissection 65 noncancerous cells 65 lung metastasis 65 biochemical recurrence 65 situ LCIS 65 activating mutations 65 benign polyps 65 SLNB 65 resected 65 fine needle aspiration 65 sarcomatoid 65 metastatic prostate 65 Lymph node 64 mediastinal 64 colorectal adenocarcinoma 64 HbF 64 hypermethylated 64 colorectal polyp 64 axillary lymph node 64 brain metastases 64 retroperitoneal 64 peritoneal carcinomatosis 64 para aortic 64 neoplastic 64 nonmelanoma skin cancers 64 K ras mutations 64 schwannomas 64 metastatic RCC 64 TRUS biopsy 64 pre malignant lesions 64 mutated K ras 64 germline mutations 64 melanoma tumors 64 cervical carcinoma 64 histopathologic examination 64 metastatic tumor 64 nephrectomy 64 breast tumors 64 epithelial ovarian 64 mesotheliomas 64 neoplasms 64 Immunohistochemical analysis 64 CaP 64 colorectal neoplasms 64 HER2 receptor 64 leiomyomas 64 neuroblastoma tumors 64 radical prostatectomy RP 64 carcinoid tumor 64 TP# mutations 64 paragangliomas 64 gadolinium enhanced 64 premalignant 64 leiomyoma 64 locoregional 64 pituitary adenomas 64 malignant polyps 64 FGFR2 64 glioblastoma tumors 64 premalignant lesions 64 adjuvant therapy 64 Hurthle cell 64 benign lesions 64 malignant lesions 64 Papillary 64 paraganglioma 64 endometrial carcinoma 64 malignant prostate 64 perineural invasion 64 metastatic disease 63 precursor lesions 63 KRAS mutation 63 KRAS mutations 63 chemoembolization 63 osteosarcomas 63 prostate tumor 63 BRAF mutation 63 HER2 gene 63 serous ovarian cancer 63 underwent resection 63 HER2 expression 63 prostate adenocarcinoma 63 prognostic marker 63 lobular carcinomas 63 BRAF V#E mutation 63 lung tumors 63 lung metastases 63 neoadjuvant 63 lymph nodes 63 invasive carcinomas 63 catheter angiography 63 HNSCC 63 anaplastic 63 androgen deprivation 63 CD# + [001] 63 ductal 63 cell carcinomas 63 carotid plaque 63 BRAF V#E 63 clinically detectable 63 endometrial cancers 63 carcinoma 63 malignant nodules 63 urothelial cancer 63 chromosomal aberrations 63 meningiomas 63 prostate tissue 63 molecular subtypes 63 TACE 63 malignant growths 63 APOL1 63 transurethral resection 63 urothelial 63 HER2 positive cancers 63 HER2 negative 63 hepatic metastases 63 cytoreductive surgery 63 metastatic neuroendocrine tumors 63 amyloid deposition 63 colorectal liver metastases 63 colorectal adenoma 63 gastric adenocarcinoma 63 breast lesions 63 TMPRSS2 ERG fusion 63 familial ALS 63 HER2 positive tumors 63 lung nodule 63 carcinoid 63 neoplastic lesions 63 adjuvant chemotherapy 62 pheochromocytoma 62 calculi 62 seminoma 62 colorectal adenomas 62 sentinel node biopsy 62 Adjuvant chemotherapy 62 pheochromocytomas 62 recurrent glioblastoma multiforme 62 metastatic prostate cancer 62 adenomas 62 ovarian carcinoma 62 breast cancer subtypes 62 nodal dissection 62 colon tumors 62 carcinoids 62 extracapsular extension 62 metaplasia 62 contralateral breast cancer 62 operable breast cancer 62 chemoresistant 62 cervical lymph nodes 62 F FDG PET 62 hyperplasia 62 malignant lesion 62 amyloid deposits 62 prostate biopsy 62 basal cell carcinoma BCC 62 thymoma 62 FDG PET 62 lung carcinomas 62 neoplasia 62 TOP2A 62 colorectal polyps 62 PrPSc 62 curative resection 62 Hepatocellular Carcinoma HCC 62 pilocytic astrocytomas 62 dysplastic 62 precancerous condition 62 thrombi 62 ASCUS 62 Metastatic 62 immunohistochemical analysis 62 hepatocellular carcinomas 62 underarm lymph nodes 62 skeletal metastases 62 bladder cancers 62 missense mutations 62 HER2 positivity 62 hyperplastic polyps 62 tumor subtypes 62 TGFBR1 * 6A 62 radioiodine therapy 62 squamous 62 malignant pleural mesothelioma 62 fibroadenoma 62 IDH1 mutation 62 mediastinoscopy 62 cytoreduction 62 lymphatic tissue 62 urine cytology 62 pleomorphic 62 hepatoma 62 situ DCIS 62 ischemic lesions 62 lymphoid 62 prognostic indicator 62 sonographically 62 pT2 62 adenocarcinoma 62 recurrent ovarian 62 malignant transformation 62 splenic 62 prostate cancers 62 excisional biopsy 62 estrogen receptor negative 62 EBRT 62 PNET 62 lymph node 62 haematopoietic 62 chromosomal mutations 62 pDCs 62 BCR ABL mutations 62 medically inoperable 62 intravenous bisphosphonates 62 squamous cell carcinoma SCC 62 hepatic metastasis 62 chemopreventive agent 62 mediastinum 62 MAPK pathway 62 BRAF gene 62 BRCA mutations 61 Endometrial 61 hepatocellular carcinoma HCC 61 microvascular disease 61 androgen receptor AR 61 endometrial hyperplasia 61 adjuvant radiation 61 TET2 61 lymphocytosis 61 PSADT 61 bladder tumors 61 endosonography 61 B7 H3 61 CagA 61 OGG1 61 hypermethylation 61 MSH2 61 IGF IR 61 immunohistochemical 61 BRCA deficient 61 EGFRvIII 61 nonmetastatic 61 CIN2 + 61 collagen VII 61 ALK mutations 61 adrenalectomy 61 submandibular gland 61 cutaneous melanoma 61 mesenteric 61 hormone receptor negative 61 fibroadenomas 61 teratoma 61 NP CRNs 61 ascites 61 Malignant tumors 61 carcinomas 61 incidentalomas 61 Brain metastases 61 neoplasias 61 precancerous polyp 61 histologic subtype 61 microdeletions 61 immunohistochemical staining 61 DCIS lesions 61 gene rearrangements 61 microsatellite instability 61 acinar cells 61 CLL cells 61 leukemic cells 61 BRCA1 mutations 61 radiochemotherapy 61 GBMs 61 atherosclerotic lesions 61 BRAF mutations 61 histological subtype 61 ovarian tumors 61 polypoid lesions 61 PTPN# 61 LRP5 61 microcalcifications 61 lymph node removal 61 papillary RCC 61 serine protease 61 endometrial 61 cervical lymph node 61 varices 61 bronchogenic carcinoma 61 oesophageal adenocarcinoma 61 biochemical relapse 61 KIT mutations 61 benign growths 61 luminal cells 61 metastatic 61 vimentin 61 TNF blocker therapy 61 cranial irradiation 61 COX2 61 Bcl xL 61 mammographically 61 Circulating tumor cells 61 KRAS oncogene 61 nephron sparing surgery 61 debulking surgery 61 hepatocellular carcinoma 61 pre cancerous growths 61 intraductal 61 autoantibodies 61 microglial 61 mTOR inhibitors 61 AGTR1 61 papillary carcinoma 61 esophagectomy 61 cytostatic 61 pancreatic cancers 61 IGF 1R 61 SPINK1 61 thyroid carcinoma 61 lung adenocarcinomas 61 infarcts 61 brain parenchyma 61 pancreatic carcinoma 61 epithelioid 61 SUVmax 61 ErbB2 61 microbleeds 61 prostate epithelial cells 61 histologically proven 61 scintigraphic 61 pT3 61 benign nodules 61 oncoprotein 61 tumorigenicity 61 invasive lobular 60 prognostic factor 60 constitutively active 60 pulmonary metastasis 60 metastatic gastric 60 familial pancreatic cancer 60 ERBB2 60 antitumor effect 60 EBV infection 60 TIMP 60 mosaicism 60 H pylori 60 prostate cancer PCa 60 mediastinal lymph nodes 60 LV dysfunction 60 mammographic density 60 gastric cardia 60 stroma 60 ccRCC 60 tNOX 60 bladder carcinoma 60 colorectal tumor 60 carotid artery thickness 60 endocrine therapies 60 viable myocardium 60 tumor cells 60 squamous cell cancers 60 PITX2 60 mutational status 60 bilateral oophorectomy 60 BRCA mutation carriers 60 histologic 60 DFMO 60 luminal 60 proto oncogene 60 carcinoid tumors 60 Sezary syndrome 60 metastatic melanomas 60 EGFR gene 60 hydronephrosis 60 papillary renal cell carcinoma 60 neuroblastomas 60 intestinal polyps 60 parathyroid 60 metastatic lymph nodes 60 estrogen receptor ER 60 GNAQ 60 BRCA2 mutation carriers 60 stage IIIB 60 axilla 60 ABCB1 60 epithelial ovarian cancer 60 orthotopic 60 hematuria 60 urothelium 60 tumor necrosis 60 prostatic 60 promoter methylation 60 lymphadenopathy 60 lymphoid cells 60 PIK3CA 60 idiopathic myelofibrosis 60 breast cancer metastasis 60 EGF receptor 60 extrahepatic 60 hypoperfusion 60 imatinib therapy 60 sleeve lobectomy 60 ependymal cells 60 myoepithelial 60 glandular tissue 60 uveal melanoma 60 thyroid nodule 60 chemosensitivity 60 monoclonal gammopathy 60 EGFR receptor 60 NKG2D 60 neovascularization 60 K ras mutation 60 iNOS 60 invasive ductal carcinoma 60 somatic mutations 60 pneumonectomy 60 colonic polyps 60 curative therapy 60 nutlin 3a 60 IDH mutations 60 TMPRSS2 ERG 60 malignancies 60 medulloblastomas 60 antiangiogenic 60 stage IIIA 60 glioma cells 60 TP# mutation 60 EphA2 60 chemoradiation 60 hepatectomy 60 Sarcomas 60 metastatic lesion 60 external beam radiotherapy 60 tumor 60 pre cancerous polyps 60 Clusterin 60 histologically confirmed 60 LHRH receptor positive 60 Radical prostatectomy 60 LRP6 60 Metastases 60 gastrointestinal stromal tumors 60 cytokeratin 60 H. pylori eradication 60 hamartoma 60 nonalcoholic steatohepatitis NASH 60 androgen suppression 60 HER2 overexpression 60 myofibroblasts 60 parenchymal 60 completely resected 60 salpingo oophorectomy 60 chlamydial infection 60 CIN3 60 distal colon 60 malignant neoplasms 60 extramedullary 60 bcl 2 60 osteochondromas 60 estrogen receptor alpha 60 nonischemic 60 choroidal neovascularization 60 neurofibromas 60 squamous cell carcinomas 60 histologic examination 60 LRAT 60 5FU 60 WT1 60 ductal cancer 60 pelvic lymph nodes 60 subclinical 60 prognostic significance 60 thymectomy 60 antiproliferative effects 60 T2 lesions 60 chemoradiotherapy 60 node dissection 60 somatostatin receptors 60 papillary 60 carotid stenosis 60 Histologically 60 NF kB pathway 60 varicoceles 59 optical colonoscopy 59 metastatic cancer 59 hematopoietic cancers 59 prostatic adenocarcinoma 59 acinar 59 atypical ductal hyperplasia 59 prognostic biomarker 59 Fas ligand 59 renal parenchyma 59 IgA deficiency 59 cancerous enlargement 59 HNPCC 59 Squamous 59 synovial tissue 59 estrogen receptor positive 59 varicocele 59 uPAR 59 seminal vesicles 59 epirubicin 59 E#F# 59 clinically localized prostate 59 partial nephrectomy 59 conventional angiography 59 colorectal gastric 59 genomic alterations 59 Epstein Barr virus EBV 59 EGFR inhibitors 59 proteolytic cleavage 59 extracapsular 59 FDG uptake 59 HG PIN 59 dexrazoxane 59 GSTM1 59 histologic diagnosis 59 T#I [002] 59 malignant neoplasm 59 BRCA mutation 59 Asymptomatic 59 infarct size 59 radical cystectomy 59 TNFa 59 HER2 amplification 59 peritoneal cancer 59 aromatase enzyme 59 basal cell cancers 59 sporadic ALS 59 #F FDG 59 pulmonary nodules 59 squamous cell lung cancer 59 prostate cancer CRPC 59 R0 resection 59 elevated CRP 59 ipsilateral 59 brain lesions 59 fibrocytes 59 CR nPR 59 GSTP1 59 seminal vesicle 59 testicular cancers 59 ductal lobular 59 pleural mesothelioma 59 TGFß 59 hypervascular tumors 59 Adjuvant therapy 59 CDK4 59 multicentric 59 carotid plaques 59 gastric cancers 59 surgically resectable 59 intrahepatic 59 prostatic tissue 59 recurrent NSCLC 59 astrocytomas 59 Recurrences 59 CIN3 + 59 orchiectomy 59 activin 59 ALCL 59 pathologic diagnosis 59 lymphoid tissue 59 osteoid 59 Barrett mucosa 59 cystic lesions 59 CIN2 59 renal carcinoma 59 NSCLC tumors 59 TIMP 1 59 N Myc 59 Carcinoma 59 TNF α 59 breast endometrial 59 axillary 59 PCNSL 59 polyps growths 59 stromal cells 59 PSA nadir 59 Helicobacter 59 scintigraphy 59 surgical excision 59 postoperative radiotherapy 59 colorectal carcinomas 59 metastatic GIST 59 adenomatous polyp 59 sCJD 59 surgically resected 59 thoracoscopic lobectomy 59 intraoperative complications 59 specific antigen PSA 59 taxane therapy 59 spontaneous regression 59 tunica vaginalis 59 PKCi 59 ectopic 59 metastatic bladder 59 amenorrhoea 59 TTR gene 59 malignant phenotype 59 Leydig cell 59 MALT lymphoma 59 total thyroidectomy 59 micronuclei 59 basal cell carcinomas 59 alkaline phosphatase ALP 59 motor neuron degeneration 59 neuroendocrine tumors 59 progesterone receptor PR 59 oligodendrogliomas 59 causal variants 59 mesangial 59 Leukemias 59 mutated KRAS gene 59 umbilical vein 59 MGd 59 precancer 59 malignant cells 59 Metastasis 59 cytopathic 59 precancers 59 metastatic malignant melanoma 59 prion infection 59 Akt activation 59 Ductal carcinoma 59 renal cysts 59 castrate resistant 59 lymphatics 59 biliary tract cancer 59 SNP rs# [002] 59 gastroesophageal junction 59 SLN biopsy 59 benign moles 59 adjuvant therapies 59 microalbuminuria 59 cholangiocarcinoma 59 transrectal ultrasound guided 59 PARP inhibition 59 #.#ng/ml 59 enucleation 59 transitional cell carcinoma 59 NAbs 59 glioma tumors 59 myeloma cells 59 pleura 59 lung adenocarcinoma 59 GnRH agonists 59 MLH1 59 unresectable 59 ERK1 2 59 gastric carcinoma 59 tumor resection 59 renal fibrosis 59 cholelithiasis 59 synovial 58 renal pelvis 58 BRCA2 mutations 58 androgen ablation 58 recurrent prostate cancer 58 parenchyma 58 necrotic core 58 malignant ovarian 58 senescent cells 58 untreated metastatic melanoma 58 Stat5 58 cytoreductive nephrectomy 58 melanoma lesions 58 pro angiogenic 58 poorer prognosis 58 ductal adenocarcinoma 58 florbetaben 58 perioperative complications 58 IGFBP 58 wedge resection 58 osteochondroma 58 Radiofrequency ablation 58 lymphangiogenesis 58 invasive coronary angiography 58 prognostic markers 58 Benign tumors 58 biliary tree 58 revascularization procedures 58 eIF 4E 58 macroalbuminuria 58 TCF#L# 58 oncogenic mutations 58 submucosal 58 cytologically confirmed 58 esophageal carcinoma 58 oligodendroglioma 58 germline mutation 58 selenium supplementation 58 subcellular compartments 58 histological diagnosis 58 aminotransferases 58 extracranial 58 mRNA expression 58 hormone receptor positive 58 colonic mucosa 58 uterine tumors 58 submucosa 58 polypoid 58 VEGF receptor 58 TAp# 58 HPV# 58 clinicopathological 58 progesterone receptor negative 58 uterine cancers 58 appendiceal 58 EGFR pathway 58 CMV infection 58 SNP rs# [001] 58 allogeneic stem cell 58 vWF 58 rectal cancers 58 immunocompetent 58 transesophageal echocardiography 58 thrombocytopenic 58 Mitomycin C 58 autologous transplants 58 lesions 58 TERT 58 trophoblasts 58 kidney cysts 58 inducible nitric oxide synthase 58 ipsilateral breast 58 cervical lesions 58 EGFR TKIs 58 cancerous breast 58 chromosomal instability 58 untreated celiac disease 58 CEACAM1 58 hypervascular 58 PTEN protein 58 tumor shrinkage 58 pituitary adenoma 58 calcified plaques 58 malignant tissue 58 liver resection 58 EGFR mutant 58 HMGA2 58 oophorectomy 58 chromosome #p#.# 58 adnexal mass 58 endoscopic ultrasonography 58 CD#c 58 situ CIS 58 surgical biopsy 58 hilar 58 unresectable tumors 58 core needle biopsy 58 arteriography 58 prophylactic cranial irradiation 58 intact parathyroid hormone 58 anti JCV antibodies 58 metastatic colorectal 58 metastatic malignant 58 mammary stem cells 58 lobules 58 elevated LDH 58 T1a 58 tumor metastases 58 Kaplan Meier analysis 58 CD# expression [001] 58 fallopian tube carcinoma 58 herpesviruses 58 spontaneously regress 58 beta1 integrin 58 invasive ductal breast cancer 58 somatic mutation 58 noncardiac 58 prognostically 58 explants 58 perivascular 58 histopathologic 58 prostate carcinogenesis 58 lobular 58 tumor biopsies 58 pre cancerous lesion 58 IL 1ß 58 astrocytic 58 endoxifen 58 medullary thyroid cancer 58 coronary angiogram 58 endostatin 58 hypopharynx 58 clinicopathologic 58 colorectal metastases 58 EGFR protein 58 mononuclear cells 58 pericardial effusion 58 58 apoptotic cells 58 mammary cancers 58 Thal Dex 58 non squamous NSCLC 58 hormone refractory 58 PTEN gene 58 seminal vesicle invasion 58 grade cervical intraepithelial 58 Cathepsin B 58 caveolae 58 mycosis fungoides 58 MAGE A3 58 myelofibrosis polycythemia vera 58 c MYC 58 complete cytogenetic response 58 TRAIL induced apoptosis 58 thyroidectomy 58 fibrocystic changes 58 tumor regrowth 58 benign noncancerous 58 gene amplification 58 esophageal squamous cell carcinoma 58 Barrett esophagus 58 TP# gene 58 anti angiogenic therapy 58 myeloproliferative diseases 58 liver transplant recipients 58 malignant tumors 58 cardiac myocytes 58 thymidylate synthase TS 58 asymptomatic carotid stenosis 58 IDH1 58 ovarian malignancy 58 gastrointestinal stromal tumors GISTs 58 stratifying patients 58 cytotoxic chemotherapy 58 ZNF# 58 HER2 positive 58 glioblastoma cells 58 melanocytic nevi 58 paroxysmal AF 58 KRAS status 58 osteoclast 58 ER alpha 58 PKC inhibitors 58 castration resistant prostate cancer 58 endometrioid 58 Rectal cancer 58 microRNA expression 58 cancerous growths 58 ductal breast cancer 58 hematopoietic cells 58 atherosclerotic disease 58 cyclin D1 58 gene polymorphisms 58 postoperative chemotherapy 58 beta subunit 58 mutated KRAS 58 FLT3 58 immunoreactivity 58 mutant protein 58 EGF receptors 58 SSc 58 KRAS mutations occur 58 clinicopathological features 58 invasive ductal 58 specific antigen 58 hematopoietic cell 58 leukaemias 58 FDG-PET/CT 58 EGFr 58 Eg5 58 pleural fluid 58 periodontal bacteria 58 lipomas 58 HLA DRB1 * 58 nonmelanoma skin cancer 58 T#M 58 mononuclear 58 plasma kallikrein 58 precancerous lesion 58 anthracyclines 58 pancreatic tumor 58 curable cancers 58 carcinoembryonic antigen 58 cerebral microbleeds 58 EBUS FNA 58 xenograft tumors 58 rs# [002] 58 sarcosine 58 allogeneic HSCT 58 eosinophil count 58 heterozygotes 58 histopathological 58 Macrophage 58 KRAS wild 58 imatinib Gleevec 58 thromboembolic 58 pancreatic endocrine 58 superficial bladder cancer 58 Chlamydia pneumoniae 58 annexin V 58 Immunohistochemical staining 58 allogeneic SCT 57 MTHFR 57 NKT cells 57 rs# [004]

Back to home page